MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2022 International Congress

    Statin use and incidence of Parkinson’s disease in women from the French E3N cohort study

    TTH. Nguyen, A. Fournier, E. Courtois, F. Artaud, S. Escolano, P. Tubert-Bitter, MC. Boutron-Ruault, I. Degaey, E. Roze, M. Canonico, I. Ahmed, ACM. Thiébaut, A. Elbaz (Villejuif, France)

    Objective: To examine whether incident statin use is associated with lower Parkinson’s disease (PD) incidence while considering the potential for reverse causation. Background: Drug repurposing…
  • 2022 International Congress

    Phase 2 study evaluating safety, PK/PD, biomarkers, and efficacy of ANX005 in patients with Huntington’s disease (HD)

    R. Kumar, D. Claassen, A. Mongan, A. Grover, B. Hoehn, P. Lin, R. Arnold, E. Cahir-Mcfarland, T. Yednock, S. Keswani (Englewood, USA)

    Objective: To assess the safety, PK/PD, exploratory biomarkers, and efficacy of ANX005 in patients with, or at risk for, manifest HD. Background: Increased complement activation…
  • 2022 International Congress

    Association between dihydropyridines and dementia conversion in Parkinson’s disease

    JH. Jung, SH. Jeong, SJ. Chung, HS. Yoo, K. Baik, BS. Ye, SJ. Kim, YH. Sohn, PH. Lee (Busan, Republic of Korea)

    Objective: To investigate the role of antihypertensive drugs, including dihydropyridines, on nigrostriatal dopamine and dementia conversion in Parkinson's disease Background: Several experimental and clinical studies…
  • 2022 International Congress

    Levodopa-carbidopa intestinal gel infusion and long-term tolerability in Parkinson’s: multicentre, international 13-year follow-up data

    V. Leta, L. Batzu, L. Williams, S. Waller, F. Garri, K. Rukavina, M. Parry, S. Jones, J. Griffith, N. Jeyakumar, M. Scharfenort, P. Odin, V. Metta, G. Chung-Faye, P. Dubois, T. Marshall, A. Zecchinelli, F. Del Sorbo, V. Viljaharju, E. Pekkonen, A. Antonini, V. Fung, K. Ray Chaudhuri (London, United Kingdom)

    Objective: To evaluate the long-term range and nature of Levodopa-carbidopa intestinal gel (LCIG) infusion-related complications in people with Parkinson’s (PwP). Background: LCIG infusion is an…
  • 2022 International Congress

    Continuous circadian intracerebroventricular administration of anaerobically preserved dopamine greatly reduces severe L-dopa-related complications in Parkinson’s disease

    C. Moreau, P. Odou, A. Demailly, G. Touzet, N. Reyns, N. Carta, C. Barthelemy, D. Lannoy, B. Palas, B. Gouges, JC. Devedjian, L. Defebvre, M. Fisichella, D. Devos (Lille, France)

    Objective: We aim to demonstrate the safety and efficacy of continuous circadian intracerebroventricular (i.c.v.) administration of anaerobic-dopamine (A-dopamine) to reduce the L-dopa-related complications (LDRC) in…
  • 2022 International Congress

    Efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease patients with motor fluctuations: a multicenter randomized open-label cross-over trial

    HJ. Chang, J. Park, S. Oh, CW. Shin, JW. Cho, JY. Lee (Seoul, Republic of Korea)

    Objective: This study aimed to assess the efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease (PD) patients with motor fluctuation. Background: Delayed…
  • 2022 International Congress

    Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson’s disease: TALISMAN study rationale and protocol

    J. Janssen Daalen, M. Meinders, B. Stunnenberg, H. Groenewoud, P. Ainslie, D. Thijssen, B. Bloem (Nijmegen, Netherlands)

    Objective: This is the first study that will assess the potential impact of hypoxia-based therapy in individuals with PD on respiratory parameters and PD symptoms.…
  • 2022 International Congress

    Adverse drug reactions to apomorphine: a worldwide pharmacovigilancedatabase analysis

    M. Auffret, C. Le Corre, LM. Scailteux, M. Vérin, E. Polard (Rennes, France)

    Objective: To determine the safety profile of apomorphine (expected vs. new signals), regardless of the indication and route of administration. Background: Adverse drug reactions (ADR)…
  • 2022 International Congress

    Variability of Plasma Levodopa Conveniently Reduced by More Frequent Administration of Smaller Doses of Carbidopa/Levodopa Using a Novel Functionally Scored Formulation

    A. Al-Sabbagh, S. Testino, M. Koga, T. Chase, K. Smith (Alpharetta, USA)

    Objective: To evaluate the pharmacokinetics (PK) of 25/100 mg carbidopa (CD)/levodopa (LD) compared to half that amount given twice as often using a new, deeply…
  • 2022 International Congress

    Phantom Pregnancy – A Novel Impulse Control Behaviour in Parkinson’s Disease: A Case Report

    H. Martin, L. Teare (Coventry, United Kingdom)

    Objective: A case report of a phantom pregnancy in a patient with Parkinson’s disease (PD) resulting from impulse control behaviour. Background: Impulse Control Disorders (ICDs)…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 34
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley